<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Povedano, Santiago Tofé</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Once-Weekly Dulaglutide Produces Superior Glycemic Control Compared with Metformin</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-12</style></pages><abstract><style  face="normal" font="default" size="100%">Efficacy and safety data from the Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus: Assessment of Weekly Administration of LY2189265 in Diabetes-3 study [AWARD-3; NCT01126580] Phase 3, randomized, double-blind, parallel-arm, monotherapy study have revealed the superiority of once-weekly dulaglutide 0.75 or 1.5 mg compared with twice-daily metformin 1000 mg in controlling glycemia in type 2 diabetes.</style></abstract><number><style face="normal" font="default" size="100%">17</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>